Noise level: Our pick for the best quiet CPAP machine is the Luna G3, but you'll want to make sure that whichever model you ...

EPS of $2.37 on $1.29 billion in sales, citing strong global demand for sleep devices, plus a boost from tariff exemptions.

A major Australian company has managed to secure a tariff exemption from the Trump Administration as the world waits to see ...

Resmed reported third quarter 2025 revenues of $1.3 billion, an increase of 8% over the same quarter the prior year.

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near-term risk from this therapy due to the higher cost and invasive surgery ...

Piper Sandler lowered the firm’s price target on ResMed (RMD) to $248 from $260 and keeps a Neutral rating on the shares. The firm notes the ...

KeyBanc analyst Brett Fishbin raised the firm’s price target on ResMed (RMD) to $274 from $269 on higher estimates, while keeping an Overweight ...

ResMed dominates healthcare devices with innovation, recurring revenues, and market leadership. See why we believe RMD stock ...

While US President Donald Trump's tariffs have sent global markets into a tailspin, medical technology companies are ...

Sleep device maker Resmed claims it is exempt from US President Donald Trump’s new tariffs as it eyes expansion in the ...

Discover ResMed's Q3 2025 earnings highlights, including 8% revenue growth, margin expansion, new product launches, and strategic investments in ...

Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder.